Document is current
Any future updates will be listed below
-
Authors
Vining, Kyle H. http://orcid.org/0000-0002-4009-879X
Marneth, Anna E.
Adu-Berchie, Kwasi http://orcid.org/0000-0002-1959-6794
Grolman, Joshua M.
Tringides, Christina M. http://orcid.org/0000-0003-2747-1200
Liu, Yutong http://orcid.org/0000-0001-5683-5451
Wong, Waihay J.
Pozdnyakova, Olga
Severgnini, Mariano
Stafford, Alexander
Duda, Georg N. http://orcid.org/0000-0001-7605-3908
Hodi, F. Stephen
Mullally, Ann
Wucherpfennig, Kai W. http://orcid.org/0000-0002-1829-302X
Mooney, David J. http://orcid.org/0000-0001-6299-1194
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K08DE025292, K99DE030084, U01CA214369)
U.S. Department of Defense (W81XWH-20-1-0904)
Deutsche Forschungsgemeinschaft (DFG FOR 2165)
European Molecular Biology Organization (ALTF 268-2017)
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (R01FD006589)
- License Information
-
More Information
Article History
Received: 15 January 2020
Accepted: 18 May 2022
First Online: 11 July 2022
Competing interests
: D.J.M. has sponsored research from Novartis, and consults and/or has stock options/stock in J&J, Samyang Corp., Lyell, Attivare, IVIVA, and Revela; none of these relate to the topic of this manuscript. Within the past 12 months, A.M. has consulted for Janssen, PharmaEssentia, Constellation and Relay Therapeutics and receives research support from Janssen and Actuate Therapeutics. The authors confirm that there are no known conflicts of interest associated with this publication and there has been no notable financial support for this work that could have influenced its outcome. The remaining authors declare no competing interests.
